[go: up one dir, main page]

CU20170168A7 - Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina - Google Patents

Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina

Info

Publication number
CU20170168A7
CU20170168A7 CUP2017000168A CU20170168A CU20170168A7 CU 20170168 A7 CU20170168 A7 CU 20170168A7 CU P2017000168 A CUP2017000168 A CU P2017000168A CU 20170168 A CU20170168 A CU 20170168A CU 20170168 A7 CU20170168 A7 CU 20170168A7
Authority
CU
Cuba
Prior art keywords
emtricitabina
pharmaceutical formulations
include tenofovir
tenofovir
pharmaceutically acceptable
Prior art date
Application number
CUP2017000168A
Other languages
English (en)
Inventor
Joanna M Koziara
Scott Mccallister
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20170168(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CU20170168A7 publication Critical patent/CU20170168A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La invención proporciona una forma de dosificación oral sólida que comprende alafenamida de tenofovir o una sal farmacéuticamente aceptable de Ia misma, y emtricitabina o una sal farmacéuticamente aceptable de Ia misma.<br />  </p>
CUP2017000168A 2015-06-30 2016-06-29 Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina CU20170168A7 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562187113P 2015-06-30 2015-06-30
US201662298373P 2016-02-22 2016-02-22
US201662301429P 2016-02-29 2016-02-29
US201662317286P 2016-04-01 2016-04-01
PCT/US2016/040158 WO2017004244A1 (en) 2015-06-30 2016-06-29 Pharmaceutical formulations comprising tenofovir and emtricitabine

Publications (1)

Publication Number Publication Date
CU20170168A7 true CU20170168A7 (es) 2018-07-05

Family

ID=56418608

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000168A CU20170168A7 (es) 2015-06-30 2016-06-29 Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina

Country Status (26)

Country Link
US (3) US20180177734A1 (es)
EP (6) EP3316868B1 (es)
JP (3) JP6667556B2 (es)
KR (2) KR102313668B1 (es)
CN (2) CN119606990A (es)
AU (3) AU2016287500B2 (es)
BR (1) BR112017027843A2 (es)
CA (1) CA2990210C (es)
CL (1) CL2017003320A1 (es)
CO (1) CO2017013293A2 (es)
CU (1) CU20170168A7 (es)
DO (1) DOP2017000306A (es)
EA (1) EA201792592A1 (es)
EC (1) ECSP17084331A (es)
ES (5) ES3007987T3 (es)
HK (1) HK1248547A1 (es)
IL (1) IL256364A (es)
MA (1) MA50541A (es)
MX (1) MX2017016806A (es)
PE (1) PE20180411A1 (es)
PH (1) PH12017502431A1 (es)
PL (5) PL3316868T3 (es)
PT (4) PT4070787T (es)
SI (4) SI4070788T1 (es)
SV (1) SV2017005601A (es)
WO (1) WO2017004244A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3067358T1 (sl) 2012-12-21 2019-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
CN108348473B (zh) 2015-11-09 2021-06-18 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
AU2018222739C1 (en) 2017-02-17 2024-10-03 Eidos Therapeutics, Inc. Processes for preparing AG-10, its intermediates, and salts thereof
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
US11191763B2 (en) 2017-03-20 2021-12-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HIV post-exposure prophylaxis
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
KR20200135996A (ko) 2018-03-23 2020-12-04 에이도스 테라퓨틱스, 인코포레이티드 Ag10을 사용하여 ttr 아밀로이드증을 치료하는 방법
CA3104695A1 (en) 2018-08-17 2020-02-20 Eidos Therapeutics, Inc. Formulations of ag10
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) * 2019-12-31 2020-03-27 常州恒邦药业有限公司 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN117338733B (zh) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 一种富马酸替诺福韦二吡呋酯片及其制备工艺
WO2025229473A1 (en) * 2024-05-01 2025-11-06 Lupin Limited Tenofovir alafenamide compositions
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法
CN119139247A (zh) * 2024-09-05 2024-12-17 安徽贝克生物制药有限公司 一种恩曲他滨丙酚替诺福韦复方片及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000587A (es) 2000-07-21 2004-04-05 Gilead Sciences Inc Profarmacos de analogos de nucleotido de fosfonato y metodos para seleccionar y elaborar los mismos.
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2004206821C1 (en) * 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR101645759B1 (ko) 2009-02-06 2016-08-04 길리애드 사이언시즈, 인코포레이티드 조합 요법용 정제
PE20141328A1 (es) 2011-08-16 2014-10-04 Gilead Sciences Inc Tenofovir alafenamida hemifumarato
US20150105350A1 (en) * 2012-02-03 2015-04-16 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
EP3033084A1 (en) * 2013-08-14 2016-06-22 ratiopharm GmbH Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (es) * 2014-06-20 2018-06-23

Also Published As

Publication number Publication date
JP6667556B2 (ja) 2020-03-18
AU2016287500B2 (en) 2019-05-02
CN119606990A (zh) 2025-03-14
AU2016287500A1 (en) 2018-01-18
PT4070787T (pt) 2023-05-22
EP4070787B1 (en) 2023-03-01
AU2019210558B2 (en) 2021-04-22
AU2021202009B2 (en) 2023-04-13
BR112017027843A2 (pt) 2018-09-04
HK1248547A1 (zh) 2018-10-19
PE20180411A1 (es) 2018-03-01
EP4070788B1 (en) 2023-03-22
EP4527467A2 (en) 2025-03-26
EP4527467A3 (en) 2025-05-21
CA2990210A1 (en) 2017-01-05
CN107847450A (zh) 2018-03-27
EP3607939A1 (en) 2020-02-12
EP3316868A1 (en) 2018-05-09
PL3607939T3 (pl) 2022-11-07
DOP2017000306A (es) 2018-01-15
ECSP17084331A (es) 2018-01-31
JP6978534B2 (ja) 2021-12-08
EA201792592A1 (ru) 2018-06-29
EP4233846A3 (en) 2023-10-04
ES2925246T3 (es) 2022-10-14
JP2020079304A (ja) 2020-05-28
US20180177734A1 (en) 2018-06-28
MA50541A (fr) 2021-04-07
US20250281412A1 (en) 2025-09-11
JP2018519297A (ja) 2018-07-19
KR102313668B1 (ko) 2021-10-19
JP2021185188A (ja) 2021-12-09
CL2017003320A1 (es) 2018-07-13
CO2017013293A2 (es) 2018-05-31
ES2945896T3 (es) 2023-07-10
PH12017502431A1 (en) 2018-07-02
SI4070787T1 (sl) 2023-07-31
IL256364A (en) 2018-02-28
CA2990210C (en) 2021-01-12
SI4070788T1 (sl) 2023-06-30
EP4233846C0 (en) 2024-12-04
ES2786549T3 (es) 2020-10-13
AU2021202009A1 (en) 2021-04-29
PL3316868T3 (pl) 2020-10-19
EP4233846A2 (en) 2023-08-30
PL4070788T3 (pl) 2023-07-10
SV2017005601A (es) 2018-05-04
KR20180021134A (ko) 2018-02-28
MX2017016806A (es) 2018-05-07
EP3607939B1 (en) 2022-06-01
US20170000807A1 (en) 2017-01-05
SI3607939T1 (sl) 2022-10-28
PT3316868T (pt) 2020-04-21
KR20200067937A (ko) 2020-06-12
KR102121329B1 (ko) 2020-06-17
EP4233846B1 (en) 2024-12-04
PT3607939T (pt) 2022-09-12
EP4070787A1 (en) 2022-10-12
WO2017004244A1 (en) 2017-01-05
PL4070787T3 (pl) 2023-07-24
PL4233846T3 (pl) 2025-03-24
ES2945345T3 (es) 2023-06-30
AU2019210558A1 (en) 2019-08-15
ES3007987T3 (en) 2025-03-21
EP3316868B1 (en) 2020-02-19
PT4070788T (pt) 2023-06-06
EP4070788A1 (en) 2022-10-12
SI3316868T1 (sl) 2020-04-30

Similar Documents

Publication Publication Date Title
CU20170168A7 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
IL264210A (en) High-strength oral cannabinoid dosage forms
EP4045480A4 (en) PHARMACEUTICAL FORMULATIONS
MX2017016802A (es) Formulaciones farmaceuticas.
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
PH12016501841A1 (en) Immunosuppressant formulation
HUP1700253A1 (hu) Szilárd orális gyógyszerkészítmények
MA55015A (fr) Formulations pharmaceutiques
ZA202006570B (en) Pharmaceutical formulations
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
GB2591396B (en) Pharmaceutical suspension for oral dosage
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
SG11202010792TA (en) Improved pharmaceutical formulations
EP3697393A4 (en) DOSAGE FORMS
EP3651800C0 (en) HYDROCOMPRESSED PHARMACEUTICAL FORMULATIONS
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
EP3880171C0 (en) IBUPROFEN CONTAINING ORAL PHARMACEUTICAL FORMULATION
EP3512507A4 (en) ORAL MEDICINAL FORMULATIONS
HUE056233T2 (hu) Ibuprofén készítmények közvetlen orális beadásra
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
EP3955907A4 (en) PHARMACEUTICAL FORMULATIONS CONTAINING P2Y14 ANTAGONISTS